Clinical Trial Update: Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical evaluation of the TriActiv ProGuard System for carotid artery stenting has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carotid Artery Stenosis

Drugs mentioned

• TriActiv ProGuard System

Snippet

Sponsor: Kensey Nash Corporation | Conditions: Carotid Stenosis | Phase 2, Phase 3 | Status: TERMINATED